BNP Paribas Financial Markets
TSHA icon

BNP Paribas Financial Markets’s Taysha Gene Therapies TSHA Stock Holding History

BNP Paribas Financial Markets’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36M Buy
640,035
+519,835
+432% +$3.08M ﹤0.01% 2201
2026
Q1 		$537K Sell
120,200
-52,282
-30% -$243K ﹤0.01% 3544
2025
Q4 		$949K Buy
172,482
+126,448
+275% +$614K ﹤0.01% 3147
2025
Q3 		$151K Buy
46,034
+27,443
+148% +$77.7K ﹤0.01% 4131
2025
Q2 		$42.9K Buy
18,591
+6,350
+52% +$13.8K ﹤0.01% 4313
2025
Q1 		$17K Sell
12,241
-11,403
-48% -$19.1K ﹤0.01% 4579
2024
Q4 		$40.9K Buy
+23,644
New +$49K ﹤0.01% 4507

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BNP Paribas Financial Markets's TSHA Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Taysha Gene Therapies (TSHA) stake by 432% in Q2 2026, buying an estimated $3.08M and bringing the position to 640,035 shares worth $4.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

BNP Paribas Financial Markets first reported a position in TSHA in Q4 2024 and has held it in 7 quarters since. 192 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • BNP Paribas Financial Markets held 640,035 shares of Taysha Gene Therapies worth $4.36M as of Q2 2026.
  • BNP Paribas Financial Markets bought 519,835 Taysha Gene Therapies shares in Q2 2026, an estimated $3.08M.
  • Taysha Gene Therapies made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2201 holding.
  • BNP Paribas Financial Markets first reported a position in Taysha Gene Therapies in Q4 2024 and has held it in 7 quarters since.
  • 192 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.